The company had already announced in July its intention to lay off around fifty people. Thursday, the unions learned that at least 30 other workers would be landed, as well as 20 external consultants whose mission will not be renewed.
The real impact of the restructuring “will however only be known once the information and consultation phase has been completed within the framework of the Renault procedure”, insisted on specifying the management in a press release.
The staff wonders about the future of the site as a whole. Novartis Pharma, which currently employs 288 workers, is experiencing its third restructuring in five years, recalls the liberal union.
Management assures, however, that “the continuation of activities on the site is not in question”.